|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Female Sexual Dysfunction - Results From Datamonitors 2005 Physician Survey
Datamonitor, June 2007, Pages: 149
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the classification guidelines, further limiting diagnosis, already hampered by embarrassment, lack of physician awareness and an unclear referral system.
Scope of this title:
Review of the disease definition, classification and key patient segmentation for female sexual dysfunction Assessment of the current unmet needs in the treatment of female sexual dysfunction Exploration of the screening, presentation and referral patterns within the female sexual dysfunction population in the 5EU and US Prescription and treatment trends among important subcategories of female sexual dysfunction, such as hypoactive sexual desire disorder (HSDD)
Highlights of this title:
Testosterone therapies are already widely used among women with hypoactive sexual desire disorder and female sexual arousal disorder. There is a significant market for a formally approved testosterone product for women, with 85% of prescribers willing to switch existing testosterone users onto an approved product. There is a distinct need for more specialized services in support of those with sexual functioning problems. There is no clear referral pathway for primary care physicians and no specialist service for patients to present directly to. This causes a barrier to presentation, diagnosis and treatment. The identification and classification of FSD is biased by physicians perception. A woman presenting with sexual difficulties could receive a variety of diagnoses or even no diagnosis at all. There is a need not only for a more holistic approach to sexual dysfunction, but also for validated and consistent tools to assess and diagnose patients.
Reasons to order your copy:
Understand key opinion leaders views on topical issues in the female sexual dysfunction market View quantified, pictorial treatment pathways of female sexual dysfunction patients in the UK, US and Spain Examine treatment trends for female sexual dysfunction subtypes, hypoactive sexual desire disorder and female sexual arousal disorder
Customers who bought this item also bought
Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Strategic Perspectives: Female Sexual Dysfunction - Are Physicians and Patients Ready For a Female Viagra?
Major Milestones: Female Sexual Dysfunction
U.S. Sexual Dysfunction Medication Markets
Womens Health Female Sexual Dysfunction
Male and female sexual dysfunction: Blockbuster indication for multiple pharmacological targets
Female Sexual Pain Disorders: Evaluation and Management
American Sexual Behavior: Demographics of Sexual Activity, Fertility, and Childbearing
Female Sexual Dysfunction Therapy Area Pipeline Report
The World Market For Sexual Disorders, 2005-2012: Traversing New Frontiers in Sexual Chemistry
Handbook of Sexual and Gender Identity Disorders
Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence
|
|
|
|
